
Trending News Today: Second Phase 3 Study Shows Positive Results for Bimekizumab in Moderate-to-Severe Psoriasis
Top news of the day from across the health care landscape.
The phase 3 BE READY study evaluating bimekizumab, an investigational dual inhibitor, for the treatment of adults with moderate-to-severe psoriasis met its co-primary endpoints,
A new study shows that the severity of disease burden and hospitalization from an influenza season does not directly affect the rate of vaccinations,
A recent review indicates that diets with more fiber and yogurt may be tied to a lower risk of developing lung cancer compared with diets that do not contain these foods,
Related to this article








